00000000nam 2200000zi 4500
0019.914232
003CaOODSP
00520230120155511
006m     o  d f      
007cr cn|||||||||
008220808t20232023oncd    ob   f000 0 eng d
020 |a9780660449364
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aHP40-320/2022E-PDF
24500|aCost-effectiveness of palivizumab prophylaxis for respiratory syncytial virus (RSV) : |ba systematic review.
264 1|a[Ottawa] : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |c2023.
264 4|c©2023
300 |a1 online resource (41 pages) : |bgraphs
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aCover title.
500 |a"Publication date: January 2023."
500 |aAt head of title: An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI).
500 |aIssued also in French under title: Rapport coût-efficacité de la prophylaxie par palivizumab pour le virus respiratoire syncytial (VRS) : un examen systématique.
504 |aIncludes bibliographical references (pages 15-18).
520 |a"Palivizumab (PVZ) prophylaxis is used as passive immunization for respiratory syncytial virus (RSV). However, due to its high acquisition costs, the value of this intervention is unclear. The objective of this study was to systematically review the cost-effectiveness of PVZ prophylaxis compared to no prophylaxis in infants under 24 months of age"--Executive summary, page 3.
650 0|aPalivizumab|zCanada|xCost effectiveness.
650 0|aRespiratory syncytial virus|zCanada.
650 0|aInfants|xDiseases|zCanada.
7102 |aPublic Health Agency of Canada, |eissuing body.
77508|tRapport coût-efficacité de la prophylaxie par palivizumab pour le virus respiratoire syncytial (VRS) : |w(CaOODSP)9.914233
85640|qPDF|s1.42 MB|uhttps://publications.gc.ca/collections/collection_2023/aspc-phac/HP40-320-2022-eng.pdf
986 |a220361